Last reviewed · How we verify

NCT04373512

Intravesical Lactobacillus to Reduce Urinary Symptoms After Spinal Cord Injury

Completed Phase 2 Last updated 13 May 2025
What this trial tests

Phase 2 trial testing Culturelle 10 Billion CFU Capsule (2 doses) in Spinal Cord Injuries in 182 participants. Completed in 14 February 2025.

Timeline
20 May 2020
Primary endpoint
14 February 2025
14 February 2025

Quick facts

Lead sponsorMedstar Health Research Institute
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment182
Start date20 May 2020
Primary completion14 February 2025
Estimated completion14 February 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Medstar Health Research Institute

Who can join

18 and older, any sex, with Spinal Cord Injuries or Neurogenic Bladder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Spinal Cord Injuries

Currently open trials in the same condition.

Other Medstar Health Research Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04373512.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing